Skip to main content
SpringerLink
Log in

Author's concluding statement

  • Correspondence
  • Published:
Infection Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cars, O. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand. J. Infect. Dis. Suppl. 74 (1991) 23–33.

    Google Scholar 

  2. Nix, D. E., Goodwin, D., Pelquin, C. A., Rotella, D. L., Schentag, J. J. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob. Agents Chemother. 35 (1991) 1953–1959.

    PubMed  Google Scholar 

  3. Donowitz, G. R., Mandell, G. L. Acute pneumonia. In:Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Principles and practice of infectious diseases. Churchill Livingstone Inc., New York 1995, 4th ed., 619–637.

    Google Scholar 

  4. Sörgel, F., Stephan, U., Wiesemann, H. G., Gottschalk, B., Stehr, C., Rey, M., Böwing, H. B., Dominick, H. C., Geldmacher von Mallinckrodt, M. High dose treatment with antibiotics in cystic fibrosis — a reappraisal with special reference to the pharmacokinetics of betalactams and new fluoroquinolones in adult CF-patients. Infection 15 (1987) 385–396.

    PubMed  Google Scholar 

  5. Wildfeuer, A., Laufen, H., Leitold, M., Zimmermann, T. Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine. J. Antimicrob. Chemother. 31 (Suppl. E) (1993) 51–56.

    Google Scholar 

  6. Foulds, G., Johnson, R. B. Selection of dose regimens of azithromycin. J. Antimicrob. Chemother. 31 (Suppl. E) (1993) 39–50.

    Google Scholar 

  7. Cooper, M. A., Nye, K., Andrews, J. M., Wise, R. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J. Antimicrob. Chemother. 26 (1990) 533–538.

    PubMed  Google Scholar 

  8. Mazzei, T., Surrenti, C., Novelli, A., Crispo, A., Fallani, S., Carlà, V., Surrenti, E., Petri, P. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J. Antimicrob. Chemother. 31 (Suppl. E) (1993) 57–63.

    Google Scholar 

  9. Kees, F., Wellenhofer, M., Grobecker, H. Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers. Infection 23 (1993) 168–172.

    Google Scholar 

  10. Davies, B. I., Maesen, F. P. V., Gubbelmans, R. Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study. J. Antimicrob. Chemother. 23 (1989) 743–751.

    PubMed  Google Scholar 

  11. Glupczynski, Y., Burette, A. Failure of azithromycin to eradicateCampylobacter pylori from the stomach because of acquired resistance during treatment. Am. J. Gastroenterol. 85 (1990) 98–99.

    PubMed  Google Scholar 

  12. Seppälä, H., Nissinen, A., Järvinen, H., Huovinen, S., Henriksson, T., Herva, E., Holm, E. E., Jakkola, M., Katila, M.-L., Klaukka, T., Kontiainen, S., Liimatainen, O., Oinonen, S., Passi-Metsomaa, L., Huovinen, P. Resistance to erythromycin in group A streptococci. N. Engl. J. Med. 326 (1992) 292–297.

    PubMed  Google Scholar 

  13. Seppälä, H., Klaukka, T., Lehtonen, R., Nenonen, E., Huovinen, P., andthe Finnish Study Group for Antimicrobial Resistance Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci. Clin. Infect. Dis. 21 (1995) 1378–1385.

    PubMed  Google Scholar 

  14. Shah, P. M., Bryskier, A. Epidemiology of resistance to macrolide antibiotics. In:Bryskier, A., Butzler, J. P., Neu, H. C., Tulkens, P. M. (eds): Macrolides — chemistry, pharmacology and clinical use. Arnette Blackwell, Paris 1993, pp. 143–166.

    Google Scholar 

  15. Physicians' Desk Reference® (PDR), Medical Economics Data Production Company, Montvale, NJ (1995), 49th ed., p. 1882.

Download references

Author information

Authors and Affiliations

  1. Max von Pettenkofer-Institut, Universität München, Pettenkoferstr. 9a, D-80336, München, Germany

    A. Bauernfeind

Authors
  1. A. Bauernfeind
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bauernfeind, A. Author's concluding statement. Infection 24, 270–271 (1996). https://doi.org/10.1007/BF01781114

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01781114

Keywords

Search

Navigation